Pharmacoepidemiology: CurrentStatus, Prospects, and Problems
Authors: Brian L. Strom, Peter Tugwell
Journal: Annals of Internal Medicine (1990)

Editorials1 August 1990Pharmacoepidemiology: CurrentStatus, Prospects, and ProblemsBrian L. Strom, MD, MPH, Peter Tugwell, MD, MScBrian L. Strom, MD, MPHSearch for more papers by this author, Peter Tugwell, MD, MScSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-113-3-179 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptModern medicine is now blessed with drug therapies that are much more powerful than before, enabling us to provide much better medical care but also to do much greater harm. Adverse drug reactions are a major source of morbidity (1) and are potentially preventable. Adverse drug reactions have been reported to cause 3% to 6% of all medical admissions (2) and as many as 160 000 deaths each year (3).After preclinical animal testing, drugs undergo three phases of clinical testing. Generally, between 500 and 3000 patients are exposed to a drug before marketing, in order to be able to...References1. Strom B. Post-marketing surveillance: an idea whose time has come. In: Melmon KL, ed. Drug Therapeutics. New York: Elsevier-North Holland; 1982:155-63. Google Scholar2. Davies D. Textbook of Adverse Drug Reactions. 3d ed. New York: Oxford University Press; 1985:4. Google Scholar3. ShapiroSloneLewisJick SDGH. Fatal drug reactions among medical inpatients. JAMA. 1971;216:467-72. CrossrefMedlineGoogle Scholar4. . The Final Report of the Joint Commission on Prescription Drug Use, Inc. Washington, DC: Joint Commission on Prescription Drug Use; 1980. Google Scholar5. Strom B. The promise of pharmacoepidemiology. Annu Rev Pharmacol Toxicol. 1987;27:71-86. CrossrefMedlineGoogle Scholar6. ErslavWintrobe AM. Detection and prevention of drug induced blood dyscrasias. JAMA. 1962;181:114-9. CrossrefMedlineGoogle Scholar7. HerbstUlfelderPoskanzer AHD. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971;284:878-81. CrossrefMedlineGoogle Scholar8. StromCarsonMorseWestSoper BJMSK. The effect of indication on hypersensitivity reactions associated with zomepirac sodium and other nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1987;30:1142-8. CrossrefMedlineGoogle Scholar9. Ticrynafen recalled. FDA Drug Bull. 1980;10:3-4. MedlineGoogle Scholar10. Suspension of benoxaprofen (Opren). Br Med J. 1982;285:519. Google Scholar11. StromWestSimCarson BSEJ. The epidemiology of the acute flank pain syndrome from suprofen. Clin Pharmacol Ther. 1989;46:693-9. CrossrefMedlineGoogle Scholar12. Marwick C. FDA ponders approaches to curbing adverse effects of drug used against cystic acne. JAMA. 1988;259:3225. CrossrefMedlineGoogle Scholar13. Koska M. JCAHO accreditation: top trouble spots for hospitals. Hospitals. 1989;63:34. Google Scholar14. Sturek J. Point-of-service computer system and drug-use evaluation: implications for pharmacy practice in ambulatory care. Am J Hosp Pharm. 1989;46:S17-20. MedlineGoogle Scholar15. Ezzell C. AZT given the green light for clinical treatment of AIDS. Nature. 1987;326:430. CrossrefMedlineGoogle Scholar16. Faich G. Adverse-drug-reaction reporting. N Engl J Med. 1986;314:1589-92. CrossrefMedlineGoogle Scholar17. SackettHaynesTugwell DRP. Clinical Epidemiology: A Basic Science for Clinical Medicine. Boston: Little, Brown; 1985. Google Scholar18. Strom B. Sample size considerations for pharmacoepidemiologic studies. In: Strom BL, ed. Pharmacoepidemiology. New York: Churchill Livingstone; 1989;27-38. Google Scholar19. MillerGreenblatt RD. Drug Effects in Hospitalized Patients. New York: Wiley; 1976. Google Scholar20. SloneShapiroMiettinen DSO. Case-control surveillance of serious illnesses attributable to ambulatory drug use. In: Colombo F, Shapiro S, Slone D, Tognoni G, eds. Epidemiological Evaluation of Drugs. Littleton, Massachusetts: PSG Publishing Company; 1977:59-70. Google Scholar21. Strom B. Medical databases in post-marketing drug surveillance. Trends in Pharmacological Sciences. 1986;7:377-80. CrossrefGoogle Scholar22. Stergachis A. Group health cooperative of Puget Sound. In: Strom BL, ed. Pharmacoepidemiology. New York: Churchill Livingstone; 1989:149-60. Google Scholar23. Friedman G. Kaiser Permanente Medical Care Program: northern California and other regions. In: Strom BL, ed. Pharmacoepidemiology. New York: Churchill Livingstone; 1989:161-72. Google Scholar24. StromCarsonMorseLeRoy BJMA. The computerized on-line Medicaid pharmaceutical analysis and surveillance system: a new resource for postmarketing drug surveillance. Clin Pharmacol Ther. 1985;38:359-64. CrossrefMedlineGoogle Scholar25. StrandWest LR. Health databases in Saskatchewan. In: Strom BL, ed. Pharmacoepidemiology. New York: Churchill Livingstone; 1989:189-200. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Brian L. Strom, MD, MPH; Peter Tugwell, MD, MScAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byHow Did Research on Medication Safety in Pregnancy Define, Develop and Advance the Field of Pharmacoepidemiology?The intriguing future of pharmacoepidemiologyReported infections after human tissue transplantation before and after new food and drug administration (FDA) regulations, United States, 2001 through June, 2010Safety Experience With Bosentan in 146 Children 2–11 Years Old With Pulmonary Arterial Hypertension: Results from the European Postmarketing Surveillance ProgramEstimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysisEffect of consumer reporting on signal detection: using disproportionality analysisInfections and human tissue transplants: review of FDA MedWatch reports 2001–2004Pharmacoepidemiology Education in US Colleges and Schools of PharmacyBayesian Data Mining Techniques: The Evidence Provided by Signals Detected in Single-Company Spontaneous Reports DatabasesRisk Management Strategies in the Postmarketing PeriodThe Periodic Safety Update Report as a Pharmacovigilance ToolChallenges in the Federal Regulation of Pain Management TechnologiesInformed Consent and the Elusive Dichotomy Between Standard and Experimental TherapyCerivastatin and the Dissemination of Adverse Event InformationInformed Consent and the Elusive Dichotomy Between Standard and Experimental TherapyIntraspinal Steroids: History, Efficacy, Accidentality, and Controversy With Review of United States Food and Drug Administration ReportsA Successful Global Drug Safety System: The Hoffmann-La Roche ExperienceLimitations and strengths of spontaneous reports dataNifedipine gastrointestinal therapeutic system (GITS) for hypertensive patients in a primary care setting: results of the Extended Release Adalat Canadian Trial (EXACT)Utilização de medicamentos por crianças atendidas em crechesPatient self-monitoring: A challenging approach to pharmacoepidemiologyA population-based Danish data resource with possible high validity in pharmacoepidemiological researchPsychoactive drug prescribing in the Tasmanian community 1 August 1990Volume 113, Issue 3Page: 179-181KeywordsAdverse reactionsClinical epidemiologyDrug marketingDrug therapyDrugsFood and Drug AdministrationMorbidityPharmacoepidemiologyPharmacology ePublished: 1 December 2008 Issue Published: 1 August 1990 PDF downloadLoading ...